Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

454

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer
Gastric Cancer
Metastatic Castration-resistant Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Urothelial Cancer
Biliary Tract Cancer

Interventions

DRUG: Datopotamab deruxtecan (Dato-DXd)
DRUG: Capecitabine
DRUG: 5-Fluorouracil
DRUG: Volrustomig
DRUG: Carboplatin
DRUG: Bevacizumab
DRUG: Rilvegostomig
DRUG: Prednisone/ prednisolone
DRUG: Cisplatin

Sponsor

AstraZeneca

Collaborators

[object Object]